September 4-7 2018
Boston, MA


Twitter logo for website footers 2

Day One
Wednesday September 6th 2017

Day Two
Thursday September 7th 2017

07.30-08.30
Breakfast & Registration

08.30-08.45
Opening Remarks

Synopsis

Shaksita Desai, Cell & Viral Immunotherapy, Hanson Wade

08.45-10.15
Industry Leaders’ Fireside Chat

Synopsis

With the recent CAR-T approval, this closed Executive leaders’ panel is your chance to get the inside track to the most exciting therapies set to hit the market. Be a fly on the wall in this exclusive session that allows you to get into the minds of these leading experts and tap into their expertise. Learn what’s next and how these pioneers will continue to innovate this space, ensuring CAR-T and TCR therapies really do deliver on their promise and potential.

10.15-10.45
Speed Networking

10.45-11.15
Refreshments

11.15-11.45 CAR19 T Cells Redirected to Target Solid Tumors Using IMPACTtm Technology

Paul Rennert, President & CSO, Aleta Biotherapeutics

11.50–12.20 Novel Targets and T-Cell Receptors for Adoptive Cell Therapy

Steffen Walter, CSO, Immatics

12.25-12.55 A Best-in-Class TCR Discovery Platform for T-cell-based Therapeutics

Mark Klinger, Head of TCR Discovery, Adaptive Therapeutics

 

12.55-14.25 Lunch & Networking

14.25-14.55 Personalized Neoantigens in the Clinic

Stephanie Goff, Staff Clinician, Surgery Branch, Rosenberg Lab, NCI

15.00-15.30 Clinical Development of CRISPR/Cas9 Gene Edited CAR & TCR T Cells

Yangbing Zhao, Director, T Cell Engineering Laboratory, University of Pennsylvania

15.35-16.05 Screening CAR T Cells for Target Specificity Using Human Cell Microarray Technology

Jim Freeth, Managing Director, Retrogenix

16.05-16.35 Afternoon Refreshments & Networking

16.40-17.10 Integration of In Situ Hybridization in the Preclinical Safety Assessment of CAR-T Cells

James Rottmann, Senior Director, Translational Development, bluebird bio

17.15-17.45 Tonic 4-1BB Costimulation in CARs Impedes T Cell Survival and Is Vector Dependent

Maksim Mamonkin, Instructor, Pathology & Immunology, Center for Cell and Gene Therapy, Baylor College of Medicine

17.50-18.50 PANEL: What Are the Next Generation Innovations to Improve Solid Tumor Efficacy?

Moderator: Sicco Popma, CEO & Founder, Creative Cell Therapies

Jennifer Brogdon, Director, Exploratory Immuno-Oncology, Novartis

Sadik Kassim, VP, Head, Development, Mustang Bio

Charles Sentman, Director, Center for Synthetic Immunity, The Geisel School of Medicine, Dartmouth

18.50-19.50 CAR-TCR Evening Drinks Reception & Poster Session (Exhibition Hall)

Following on from Day 1 of the Summit join your friends, colleagues and clients for a drink at this data rich, science driven session.

Review scientific posters, which present the most innovative CAR-TCR science.

11.15–11.45 Translational Insights into Overcoming Challenges in Solid Tumor Targeting with CAR Therapy

Jennifer Brogdon, Director, Exploratory Immuno-Oncology, Novartis

11.50–12.20 Piggybac-Manufactured CAR-T Therapeutic Against Multiple Myeloma Exhibits Improved Durability

Devon Shedlock, Senior Director, Immuno- Oncology, Poseida Therapeutics

12.25-12.55 Novel Approaches to CAR-T Cell Platform

Vita Golubovskaya, Director, R&D, ProMab Biotechnologies

12.55-14.25 Lunch

14.25-14.55 TRuC™-T Cells: A New Class of Engineered T Cells for Solid Tumor Therapy

Robert Hofmeister, CSO, TCR2 Therapeutics

15.00-15.30 Imaging CAR T Cells With a Dual Function PET Reporter Gene

Michael Farwell, Assistant Professor, Radiology, University of Pennsylvania

15.35-16.05 Acoustic Cell Processing: A Disruptive Technology for Cell and Gene Therapy Applications

John Rozembersky, VP Marketing & Application Technologies, FloDesign Sonics

16.05-16.35 Afternoon Refreshments & Networking

16.40-17.10 Advancing the Discovery of Immunotherapeutics with Large Scale, Multiplexed Experiments on Cells and Proteins of the Immune System

Tom Duensing, CTO, Intellicyt

Amy Gilbert, Senior Scientist, Cell Design Labs

17.15-17.45 Moving Forward to the Future: Industrializing CAR-T Therapy with Off-the-Shelf Technology

Lei Xiao, Founder, President & CSO, Innovative Cellular Therapeutics

17.50-18.50 PANEL: What Aspects of Patient Selection or Pretreatment Recruitment Can Impact Clinical Development & Trials

Marcela Maus, Director, Cellular Immunotherapy, Massachusetts General Hospital Cancer Center

Bruce Levine, Director, Clinical Cell & Vaccine Production Facility, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania

Chris Haqq, CSO, Atara Biotherapeutics

Sean Mackay, CEO, Isoplexis

18.50-19.50 CAR-TCR Evening Drinks Reception & Poster Session (Exhibition Hall)

Following on from Day 1 of the Summit join your friends, colleagues and clients for a drink at this data rich, science driven session.

Review scientific posters, which present the most innovative CAR-TCR science.

11.15-11.45 Fill the Gap to Share the Success

Qinhua Cindy Ru, Vice President & Chief Scientific Officer, CARsgen Therapeutics

11.50-12.20 Optimizing CAR T Cell Therapy Across MHC Barriers

Arnab Ghosh, Hematology and Medical Oncology Fellow, Memorial Sloan Kettering Cancer Center

12.25-12.55 Process Automation Solutions for Patient-Scale Therapies

Nina Bauer, Commercial Development Lead, Autologous Cell Therapy, Lonza

12.55-14.25 Lunch

14.25-14.55 Applying Lifecycle Concepts to T Cell Therapy Product Development

Michael Blackton, Vice President, Quality Affairs, CMC, Adaptimmune

15.00-15.30 Enabling High-Throughput Process Development With an Extended Cytotox Assay

Geoff Hodge, CTO, Unum Therapeutics

15.35-16.05 Innovative Material Options to Fuel Advances in CAR-T Therapies via Automation

Claudia Zylberberg, CEO, Akron Biotech

16.05-16.35 Afternoon Refreshments & Networking

16.40-17.10 On-Demand and On-Site Rapid Multi-Parametric Cell Characterization

Bala Manian, Executive Chairman, LeukoDx Inc

17.15-17.45 An Automated Method for TCR Isolation and Initial Characterization

Markus Dangl, SVP, Research & Pre-Clinical Development, Medigene

17.50-18.50 PANEL: How Can We Ensure Product Consistency Every Time?

Michael Blackton, VP, Quality Affairs, CMC, Adaptimmune

Geoff Hodge, CTO, Unum Therapeutics

Rodney Rietze, Lead, cGMP, Process Automation, Novartis

Mike Stella, COO, Cognate Bioservices

18.50-19.50 CAR-TCR Evening Drinks Reception & Poster Session (Exhibition Hall)

Following on from Day 1 of the Summit join your friends, colleagues and clients for a drink at this data rich, science driven session.

Review scientific posters, which present the most innovative CAR-TCR science.

11.15-11.45 Building a Commercial Engineered T Cell Therapy Strategy

Helen Tayton-Martin, CBO, Adaptimmune

11.50-12.20 CAR T Cell Therapy for Brain Tumors: Logistical Challenges and Opportunities

Sadik Kassim, VP, Head, Development, Mustang Bio

12.25-12.55 Cryogenic Logistics and CAR-T Commercialization; Key Fleet Management Considerations

Mark Sawicki, Chief Commercial Officer, Cryoport

12.55-14.25 Lunch

14.25-.14.55 Voluntary Accreditation of Immune Effector Cell Programs: From Clinical Trials to Licensure and Beyond

Phyllis Warkentin, CMO, FACT

15.00-15.30 Market Access Implications of Cell Therapy

Anna Cameron, Market Access & Healthcare Solutions Director, Oncology, GSK

15.35-16.05 Keeping the Patient Central in Personalized Medicine: How Patient Case Management Is Essential to Cell Therapy Supply Chain Delivery

Molly McCormick, Vice President, Case Management & Operations Services, Be The Match BioTherapies

16.05-16.35 Afternoon Refreshments & Networking

16.40-17.10 Enabling Commercialization Using Cloud-Deployed Technology

Heidi Hagen, Co-Founder & CSO, Vineti

17.15-17.45 Ethical Considerations in the Translation of CAR-T Cell Therapies

 Aaron Levine, Associate Professor, School of Public Policy, Georgia Tech

17.50-18.50 PANEL: What Infrastructures Need to Be in Place to Ensure Successful Commercial Delivery of CAR-TCR Therapies

Kimberly Freeman, VP, Commercial Strategy & Planning, Adaptimmune

Phyllis Warkentin, CMO, FACT

Robert Tressler, VP, Laboratories, San Diego Blood Bank on behalf of Blood Centers of America

18.50-19.50 CAR-TCR Evening Drinks Reception & Poster Session (Exhibition Hall)

Following on from Day 1 of the Summit join your friends, colleagues and clients for a drink at this data rich, science driven session.

Review scientific posters, which present the most innovative CAR-TCR science.